Juvenile psoriatic arthritis
Information
- Disease name
- Juvenile psoriatic arthritis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04527380 | Active, not recruiting | Phase 3 | A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | April 13, 2021 | April 24, 2028 |
| NCT03769168 | Active, not recruiting | Phase 3 | An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) | June 7, 2019 | November 27, 2024 |
| NCT05252533 | Completed | Phase 1 | A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis | May 24, 2022 | January 26, 2024 |
| NCT03031782 | Completed | Phase 3 | Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) | May 23, 2017 | November 9, 2020 |
| NCT05545839 | Recruiting | N/A | Transition to Adulthood Through Coaching and Empowerment in Rheumatology | October 17, 2022 | April 2025 |
| NCT05767047 | Recruiting | Phase 3 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis | March 23, 2023 | December 29, 2032 |
| NCT06100744 | Recruiting | Phase 3 | A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | January 16, 2024 | October 7, 2028 |